Literature DB >> 3189454

Sedative and hypnotic effects of oral administration of micronized progesterone may be mediated through its metabolites.

E S Arafat1, J T Hargrove, W S Maxson, D M Desiderio, A C Wentz, R N Andersen.   

Abstract

Progesterone and its metabolites were measured in serum extracts by radioimmunoassay and gas chromatography-mass spectrometry, respectively, after ingestion of micronized progesterone by eight postmenopausal women. One subject received 400 mg of micronized progesterone orally that induced a hypnotic state that lasted for approximately 2 hours. Blood samples were drawn periodically from all subjects for measurement of progesterone and its metabolites in serum. Levels of serum progesterone and its metabolites increased significantly from baseline values and reached a peak between 2 and 6 hours after oral progesterone administration. Significant quantities of five compounds (progesterone, 5 alpha-pregnan-3 alpha-ol-20-one, 5 beta-pregnan-3 alpha-ol-20-one, 5 beta-pregnan-3 alpha,20 beta-diol, and 5 beta-pregnan-3 alpha-ol-11,20-dione) that have been reported to possess anesthetic qualities were identified. The sedative and hypnotic effects of oral administration of progesterone may be mediated through those compounds.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3189454     DOI: 10.1016/0002-9378(88)90448-6

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  12 in total

1.  A placebo-controlled study of effects of oral progesterone on performance and mood.

Authors:  E W Freeman; L Weinstock; K Rickels; S J Sondheimer; C Coutifaris
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

Review 2.  Hormone replacement therapy in the aged. A state of the art review.

Authors:  S Jacobs; T C Hillard
Journal:  Drugs Aging       Date:  1996-03       Impact factor: 3.923

3.  Progesterone co-administration in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and taper outcome.

Authors:  E Schweizer; W G Case; F Garcia-Espana; D J Greenblatt; K Rickels
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

4.  Sleep, Hormones, and Circadian Rhythms throughout the Menstrual Cycle in Healthy Women and Women with Premenstrual Dysphoric Disorder.

Authors:  Ari Shechter; Diane B Boivin
Journal:  Int J Endocrinol       Date:  2010-01-18       Impact factor: 3.257

5.  Maternity blues and major endocrine changes: Cardiff puerperal mood and hormone study II.

Authors:  B Harris; L Lovett; R G Newcombe; G F Read; R Walker; D Riad-Fahmy
Journal:  BMJ       Date:  1994-04-09

6.  Anxiolytic properties of endogenously occurring pregnanediols in two rodent models of anxiety.

Authors:  E Carboni; S Wieland; N C Lan; K W Gee
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

Review 7.  Neurobehavioural complications of sleep deprivation: Shedding light on the emerging role of neuroactive steroids.

Authors:  Roberto Frau; Francesco Traccis; Marco Bortolato
Journal:  J Neuroendocrinol       Date:  2019-09-30       Impact factor: 3.627

8.  Comparison of intravaginal progesterone gel and intramuscular 17-α-hydroxyprogesterone caproate in luteal phase support.

Authors:  Funda Satir; Tayfun Toptas; Murat Inel; Munire Erman-Akar; Omur Taskin
Journal:  Exp Ther Med       Date:  2013-04-04       Impact factor: 2.447

9.  Comparison of Subcutaneous and Vaginal Progesterone Used for Luteal Phase Support in Patients Undergoing Intracytoplasmic Sperm Injection Cycles.

Authors:  Saghar Salehpour; Nasrin Saharkhiz; Leila Nazari; Ali Sobhaneian; Sedighe Hosseini
Journal:  JBRA Assist Reprod       Date:  2021-04-27

10.  Duration of luteal support (DOLS) with progesterone pessaries to improve the success rates in assisted conception: study protocol for a randomized controlled trial.

Authors:  Rafet Gazvani; Richard Russell; Yasmin Sajjad; Zarko Alfirevic
Journal:  Trials       Date:  2012-07-26       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.